Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Changes in the antibiotic susceptibility of anaerobic bacteria from 2007-2009 to 2010-2012 based on the CLSI methodology.

Hastey CJ, Boyd H, Schuetz AN, Anderson K, Citron DM, Dzink-Fox J, Hackel M, Hecht DW, Jacobus NV, Jenkins SG, Karlsson M, Knapp CC, Koeth LM, Wexler H, Roe-Carpenter DE; From the Ad Hoc Working Group on Antimicrobial Susceptibility Testing of Anaerobic Bacteria of CLSI.

Anaerobe. 2016 Dec;42:27-30. doi: 10.1016/j.anaerobe.2016.07.003. Epub 2016 Jul 15.

2.

Cefazolin as a class representative for oral cephalosporins and uncomplicated urinary tract infections caused by indicated Enterobacteriaceae.

Schuetz AN, Brasso WB, Crandon JL, Hardy DJ, Jenkins SG, Jones RN, Knapp CC, Reller LB; Ad Hoc Oral Cephalosporin Working Group of the Subcommittee on Antimicrobial Susceptibility Testing of the CLSI.

Diagn Microbiol Infect Dis. 2013 Dec;77(4):381-2. doi: 10.1016/j.diagmicrobio.2013.08.024. Epub 2013 Oct 3. No abstract available.

PMID:
24091106
3.

Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values.

Pfaller MA, Chaturvedi V, Diekema DJ, Ghannoum MA, Holliday NM, Killian SB, Knapp CC, Messer SA, Miskou A, Ramani R.

Diagn Microbiol Infect Dis. 2012 Aug;73(4):365-8. doi: 10.1016/j.diagmicrobio.2012.05.008. Epub 2012 Jun 20.

PMID:
22726528
4.

Multisite reproducibility of the broth microdilution method for susceptibility testing of Nocardia species.

Conville PS, Brown-Elliott BA, Wallace RJ Jr, Witebsky FG, Koziol D, Hall GS, Killian SB, Knapp CC, Warshauer D, Van T, Wengenack NL, Deml S, Woods GL.

J Clin Microbiol. 2012 Apr;50(4):1270-80. doi: 10.1128/JCM.00994-11. Epub 2012 Jan 4.

5.

Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.

Pfaller MA, Andes D, Arendrup MC, Diekema DJ, Espinel-Ingroff A, Alexander BD, Brown SD, Chaturvedi V, Fowler CL, Ghannoum MA, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Walsh TJ.

Diagn Microbiol Infect Dis. 2011 Jul;70(3):330-43. doi: 10.1016/j.diagmicrobio.2011.03.002. Epub 2011 May 4. Review.

PMID:
21546199
6.

Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods.

Pfaller MA, Diekema DJ, Ghannoum MA, Rex JH, Alexander BD, Andes D, Brown SD, Chaturvedi V, Espinel-Ingroff A, Fowler CL, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Sheehan DJ, Walsh TJ; Clinical and Laboratory Standards Institute Antifungal Testing Subcommittee.

J Clin Microbiol. 2009 Oct;47(10):3142-6. doi: 10.1128/JCM.00940-09. Epub 2009 Aug 19.

7.

Correlation of cefoxitin MICs with the presence of mecA in Staphylococcus spp.

Swenson JM, Brasso WB, Ferraro MJ, Hardy DJ, Knapp CC, Lonsway D, McAllister S, Reller LB, Sader HS, Shortridge D, Skov R, Weinstein MP, Zimmer BL, Patel JB.

J Clin Microbiol. 2009 Jun;47(6):1902-5. doi: 10.1128/JCM.02304-08. Epub 2009 Apr 8.

8.

Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method.

Ostrosky-Zeichner L, Rex JH, Pfaller MA, Diekema DJ, Alexander BD, Andes D, Brown SD, Chaturvedi V, Ghannoum MA, Knapp CC, Sheehan DJ, Walsh TJ.

Antimicrob Agents Chemother. 2008 Nov;52(11):4175-7. doi: 10.1128/AAC.00420-08. Epub 2008 Sep 22.

9.

Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.

Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, Rex JH, Alexander BD, Andes D, Brown SD, Chaturvedi V, Ghannoum MA, Knapp CC, Sheehan DJ, Walsh TJ.

J Clin Microbiol. 2008 Aug;46(8):2620-9. doi: 10.1128/JCM.00566-08. Epub 2008 Jun 25.

10.

Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin.

Pfaller MA, Chaturvedi V, Diekema DJ, Ghannoum MA, Holliday NM, Killian SB, Knapp CC, Messer SA, Miskov A, Ramani R.

J Clin Microbiol. 2008 Jul;46(7):2155-9. doi: 10.1128/JCM.00493-08. Epub 2008 May 7.

11.

Detection of inducible clindamycin resistance in staphylococci by broth microdilution using erythromycin-clindamycin combination wells.

Swenson JM, Brasso WB, Ferraro MJ, Hardy DJ, Knapp CC, McDougal LK, Reller LB, Sader HS, Shortridge D, Skov R, Weinstein MP, Zimmer BL, Patel JB.

J Clin Microbiol. 2007 Dec;45(12):3954-7. Epub 2007 Oct 17.

12.

Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent.

Rennie RP, Koeth L, Jones RN, Fritsche TR, Knapp CC, Killian SB, Goldstein BP.

J Clin Microbiol. 2007 Oct;45(10):3151-4. Epub 2007 Aug 1.

13.

Clinical evaluation of the Sensititre YeastOne plate for testing susceptibility of filamentous fungi to posaconazole.

Patel R, Mendrick C, Knapp CC, Grist R, McNicholas PM.

J Clin Microbiol. 2007 Jun;45(6):2000-1. Epub 2007 Apr 11.

14.

Influence of polysorbate-80 when determining the tigecycline MIC by the reference method.

Jones RN, Knapp CC, Dowzicky MJ.

Diagn Microbiol Infect Dis. 2007 May;58(1):145-6. Epub 2007 Mar 26. No abstract available.

PMID:
17368804
15.
17.

Multisite reproducibility of MIC results by the Sensititre YeastOne colorimetric antifungal susceptibility panel.

Pfaller MA, Messer SA, Hollis RJ, Espinel-Ingroff A, Ghannoum MA, Plavan H, Killian SB, Knapp CC.

Diagn Microbiol Infect Dis. 1998 Aug;31(4):543-7.

PMID:
9764393
18.

Antimicrobial susceptibility testing of a clinical isolate of vancomycin-dependent enterococcus using D-alanine-D-alanine as a growth supplement.

Sng LH, Cornish N, Knapp CC, Ludwig MD, Hall GS, Washington JA.

Am J Clin Pathol. 1998 Apr;109(4):399-403.

PMID:
9535392
20.

The emergence of Neisseria gonorrhoeae with decreased susceptibility to ciprofloxacin in Cleveland, Ohio: epidemiology and risk factors.

Gordon SM, Carlyn CJ, Doyle LJ, Knapp CC, Longworth DL, Hall GS, Washington JA.

Ann Intern Med. 1996 Sep 15;125(6):465-70.

PMID:
8779458
21.

Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against gram-negative bacilli.

Pohlman JK, Knapp CC, Ludwig MD, Washington JA.

Diagn Microbiol Infect Dis. 1996 Sep;26(1):29-33.

PMID:
8950526
22.

Evaluation of Vitek GPS-SA card for testing of oxacillin against borderline-susceptible staphylococci that lack mec.

Knapp CC, Ludwig MD, Washington JA, Chambers HF.

J Clin Microbiol. 1996 Jul;34(7):1603-5.

24.

Evaluation of BBL crystal MRSA ID system.

Knapp CC, Ludwig MD, Washington JA.

J Clin Microbiol. 1994 Oct;32(10):2588-9.

25.

Bactericidal activities of DU-6859a and clinafloxacin (CI-960) against staphylococci.

Forstall GJ, Knapp CC, Washington JA.

Antimicrob Agents Chemother. 1994 Aug;38(8):1868-70.

26.
27.

Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime.

Washington JA, Jones RN, Gerlach EH, Murray PR, Allen SD, Knapp CC.

Antimicrob Agents Chemother. 1993 Aug;37(8):1696-700.

28.

Comparison of vidas Clostridium difficile toxin-A assay and premier C. difficile toxin-A assay to cytotoxin-B tissue culture assay for the detection of toxins of C. difficile.

Knapp CC, Sandin RL, Hall GS, Ludwig MD, Rutherford I, Washington JA.

Diagn Microbiol Infect Dis. 1993 Jul;17(1):7-12.

PMID:
8359010
32.

Development of Neisseria gonorrhoeae in vitro susceptibility test methods for cefixime including quality control guidelines.

Jones RN, Gerlach EH, Koontz FP, Murray PR, Pfaller MA, Washington JA, Erwin ME, Knapp CC.

Diagn Microbiol Infect Dis. 1991 Sep-Oct;14(5):383-8.

PMID:
1797455
33.

Activity of new quinolones against ciprofloxacin-resistant staphylococci.

Forstall GJ, Knapp CC, Washington JA.

Antimicrob Agents Chemother. 1991 Aug;35(8):1679-81.

34.

In vitro activity of metronidazole against Helicobacter pylori as determined by agar dilution and agar diffusion.

Knapp CC, Ludwig MD, Washington JA.

Antimicrob Agents Chemother. 1991 Jun;35(6):1230-1.

35.

Interpretive criteria and quality control guidelines for Neisseria gonorrhoeae susceptibility test standardization for cefotetan.

Jones RN, Gerlach EH, Koontz FP, Murray PR, Pfaller MA, Washington JA, Erwin ME, Knapp CC.

J Clin Microbiol. 1991 Feb;29(2):363-6.

36.

Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin.

Chaudhry AZ, Knapp CC, Sierra-Madero J, Washington JA.

Antimicrob Agents Chemother. 1990 Sep;34(9):1843-5.

37.

Comparative in vitro activity of cefoperazone and various combinations of cefoperazone/sulbactam.

Knapp CC, Sierra-Madero J, Washington JA.

Diagn Microbiol Infect Dis. 1990 Jan-Feb;13(1):45-9.

PMID:
2331849
38.
39.
41.

Comparative activity of newer antibiotics against gram-negative bacilli.

Knapp CC, Washington JA.

Cleve Clin J Med. 1989 Mar-Apr;56(2):161-6.

PMID:
2731335
42.

Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone.

Knapp CC, Sierra-Madero J, Washington JA.

Antimicrob Agents Chemother. 1988 Dec;32(12):1896-8.

43.

In vitro comparison of activity of cefixime with activities of other orally administered antimicrobial agents.

Knapp CC, Washington JA.

Cleve Clin J Med. 1988 Sep-Oct;55(5):477-82. No abstract available. Erratum in: Cleve Clin J Med 1990 Mar-Apr;57(2):204.

PMID:
3219796
44.
45.

Characterization of resistance phenotype and cephalosporin activity in oxacillin-resistant Staphylococcus aureus.

Mateos-Mora M, Knapp CC, Washington JA 2nd.

Antimicrob Agents Chemother. 1988 Feb;32(2):170-4.

46.

In vitro activities of LY163892, cefaclor, and cefuroxime.

Knapp CC, Washington JA 2nd.

Antimicrob Agents Chemother. 1988 Jan;32(1):131-3.

47.
48.

Rapid identification of Staphylococcus epidermidis.

Woods GL, Hall GS, Rutherford I, Pratt K, Knapp CC.

Am J Clin Pathol. 1987 Apr;87(4):525-8.

PMID:
3103421
49.

Antistaphylococcal activity of a cyclic peptide, LY146032, and vancomycin.

Knapp CC, Washington JA 2nd.

Antimicrob Agents Chemother. 1986 Dec;30(6):938-9.

50.

Detection of methicillin-resistant Staphylococcus epidermidis.

Woods GL, Hall GS, Rutherford I, Pratt KJ, Knapp CC.

J Clin Microbiol. 1986 Sep;24(3):349-52.

Supplemental Content

Loading ...
Support Center